Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Recruiting
N/A
Interventional Study
Multiple Myeloma
Total Knee Replacement
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 32 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis. Following the publication of the AVERT clinical study, Apixaban is strongly recommended as a prophylactic treatment option for patients with cancer, based on high quality of evidence and a favorable efficacy/safety profile. A multicenter and ancillary study -…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years old,
* Signed informed consent,
* Patient covered by a social security scheme.
* Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban,
* Group 2 : patient requiring a surgery for total knee replac…
Contacts